Edition:
United Kingdom

Brainstorm Cell Therapeutics Inc (BCLI.OQ)

BCLI.OQ on NASDAQ Stock Exchange Capital Market

4.11USD
22 Mar 2019
Change (% chg)

$0.07 (+1.73%)
Prev Close
$4.04
Open
$4.09
Day's High
$4.16
Day's Low
$4.05
Volume
21,047
Avg. Vol
14,225
52-wk High
$5.34
52-wk Low
$2.95

Latest Key Developments (Source: Significant Developments)

Brainstorm Cell Therapeutics Announces Successful Interim Safety Analysis In Phase 3 Trial Of Nurown Therapy For ALS
Thursday, 23 Aug 2018 

Aug 23 (Reuters) - Brainstorm Cell Therapeutics Inc ::BRAINSTORM CELL THERAPEUTICS ANNOUNCES SUCCESSFUL INTERIM SAFETY ANALYSIS IN PHASE 3 TRIAL OF NUROWN® THERAPY FOR ALS.BRAINSTORM CELL THERAPEUTICS INC - DSMB INDICATED THERE WERE NO SIGNIFICANT SAFETY CONCERNS AND RECOMMENDED THAT TRIAL CONTINUE, AS PLANNED.BRAINSTORM CELL THERAPEUTICS - ANTICIPATE COMPLETING ENROLLMENT BY MID 2019, WHICH WOULD THEN PUS US TO FILE BLA FOR US FDA APPROVAL.BRAINSTORM CELL THERAPEUTICS-DSMB COMPLETED PRE-SPECIFIED INTERIM ANALYSIS OF SAFETY OUTCOMES FOR PARTICIPANTS TREATED WITH NUROWN IN ALS PHASE 3 TRIAL.  Full Article

Brainstorm Cell Therapeutics Posts Q2 Loss Per Share $0.16
Monday, 23 Jul 2018 

July 23 (Reuters) - Brainstorm Cell Therapuetics Inc ::BRAINSTORM ANNOUNCES FINANCIAL RESULTS FOR THE SECOND QUARTER OF 2018 AND PROVIDES A CORPORATE UPDATE.Q2 LOSS PER SHARE $0.16.  Full Article

Brainstorm Cell Therapuetics Files Prospectus Relates To Resale By Selling Securityholders Of Up To 2.46 Mln Shares Of Co's Common Stock
Friday, 29 Jun 2018 

June 29 (Reuters) - Brainstorm Cell Therapuetics Inc ::BRAINSTORM CELL THERAPUETICS FILES PROSPECTUS RELATES TO RESALE BY SELLING SECURITYHOLDERS OF UP TO 2.46 MILLION SHARES OF CO'S COMMON STOCK - SEC FILING.  Full Article

Brainstorm Cell Received Good Manufacturing Practice Approval From Israel Ministry Of Health
Thursday, 4 Jan 2018 

Jan 4 (Reuters) - Brainstorm Cell Therapuetics Inc ::BRAINSTORM CELL THERAPUETICS - RECEIVED GOOD MANUFACTURING PRACTICE APPROVAL FROM ISRAEL MINISTRY OF HEALTH FOR ISRAELI CONTRACT MANUFACTURING FACILITY.BRAINSTORM CELL THERAPUETICS INC - APPROVAL ADVANCES CO'S APPLICATION TO ISRAEL MOH FOR TREATMENT OF ALS PATIENTS IN ISRAEL FOR A FEE.  Full Article

Brainstorm Cell Therapuetics names Eyal Rubin CFO
Thursday, 2 Nov 2017 

Nov 2 (Reuters) - Brainstorm Cell Therapuetics Inc :Brainstorm strengthens executive team: appoints Eyal Rubin as chief financial officer.Eyal Rubin joins co from Teva Pharmaceutical Industries Ltd.  Full Article

Brainstorm reports Q3 loss per share of $0.13
Tuesday, 17 Oct 2017 

Oct 17 (Reuters) - Brainstorm Cell Therapuetics Inc :Brainstorm announces third quarter 2017 financial results.Q3 loss per share $0.13.  Full Article

BrainStorm gets FDA okay for stem cell trial in MS patients

TEL AVIV, Dec 17 BrainStorm Cell Therapeutics Inc has received approval from the U.S. Food and Drug Administration to begin a clinical trial of its experimental stem cell treatment in patients with progressive multiple sclerosis.